<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2-887-13
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2013
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ENABLEX 15MG PROLONGED RELEASE TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DARIFENACIN HYDROBROMIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Prolonged-release tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        140.3
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ASPEN Bad Oldesloe GmbH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ASPEN Bad Oldesloe GmbH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ASPEN PHARMA TRADING LIMITED (APTL)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G04BD10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>1.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>What Enablex is and what it is used for:</strong></p><p><strong>How Enablex works:</strong></p><p>Enablex reduces the activity of an overactive bladder. This enables you to wait longer before you go to the toilet and it increases the amount of urine that your bladder can hold.</p><p><strong>What Enablex can be used for:</strong></p><p>Enablex belongs to a class of medicines which relax the muscles of the bladder. It is used in adults for the treatment of the symptoms of overactive bladder conditions - such as a sudden urge to rush to the toilet, needing to go to the toilet frequently and/or not getting to the toilet in time and wetting yourself (urge incontinence).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>2.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Before you take Enablex:</strong></p><p><strong>Do not take Enablex:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic (hypersensitive) to darifenacin or any of the other ingredients of Enablex.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from urinary retention (inability to empty your bladder).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have gastric retention (problems emptying the contents of the stomach).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from uncontrolled narrow-angle glaucoma (high pressure in the eyes with loss of eyesight that is not being adequately treated).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have myasthenia gravis (a disease marked by abnormal tiredness and weakness of selected muscles).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have severe ulcerative colitis or toxic megacolon (acute dilation of the colon due to complication of infection or inflammation).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have severe liver problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There are some medicines such as ciclosporin (a medicine used in transplantation to prevent organ rejection or for other conditions, e.g. rheumatoid arthritis or atopic dermatitis), verapamil (a medicine used to lower blood pressure, to correct heart rhythm or to treat angina pectoris), antifungal medicines (e.g. ketoconazole and itraconazole) and some antiviral medicines (e.g.ritonavir) that must not be taken with Enablex.</p><p><strong>Take special care with Enablex:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have autonomic neuropathy (damage to the nerves that communicate between the brain and internal organs, muscles, skin, and blood vessels to regulate vital functions, including the heart rate, blood pressure and bowel function) &ndash; your doctor will have told you if you have this:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have heartburn and belching.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have difficulties in passing urine and a weak stream of urine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have severe constipation (less than or equal to 2 bowel movements per week).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a digestive motility disorder.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have an obstructive gastrointestinal disorder (any obstruction of the passage of intestinal or gastric contents, such as narrowing of the pylorus, the lower part of the stomach) &ndash; your doctor will have told you if you have this.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking medicinal products that can cause or worsen inflammation of the oesophagus such as oral bisphosphonates (a class of medicinal products that prevent the loss of bone mass and are used to treat osteoporosis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are receiving treatment for narrow-angle glaucoma.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have liver problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have kidney problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have heart diseases.</p><p>If any of these apply to you, tell your doctor before you take Enablex.</p><p>During treatment with Enablex, tell your doctor straight away and stop taking Enablex if you experience swelling of the face, lips, tongue and/or throat (signs of angioedema).</p><p>Use in children (age below 18 years)</p><p>Enablex is not recommended for use in children.</p><p><strong>Taking other medicines with Enablex:</strong></p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. This is particularly important if you are taking any of the following as your doctor may need to adjust your dose of Enablex and/or the other product:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain antibiotics (e.g. erythromycin, clarithromycin and rifampicin),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antifungal medicines (e.g. ketoconazole and itraconazole),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antiviral medicines (e.g. nelfinavir and ritonavir),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antipsychotic medicines (e.g. thioridazine),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain antidepressants (e.g. imipramine),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain anticonvulsants (carbamazepine, barbiturates),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain medicines used to treat heart problems (e.g. flecainide, verapamil and digoxin),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other antimuscarinic medicines (e.g. tolterodine, oxybutynin and flavoxate).</p><p>Please also inform your doctor if you are taking products containing St John&rsquo;s wort.</p><p><strong>Taking Enablex with food and drink:</strong></p><p>Eating food has no effect on Enablex. Grapefruit juice may interact with Enablex. However, the adjustment of Enablex doses is not necessary.</p><p><strong>Pregnancy and breast-feeding:</strong></p><p>If you are pregnant or think you may be pregnant, tell your doctor. Enablex is not recommended during pregnancy.</p><p>If you are breast-feeding, ask your doctor for advice. Enablex should be taken with caution while breast-feeding.</p><p><strong>Driving and using machines:</strong></p><p>Enablex may cause effects such as dizziness, blurred vision, trouble sleeping or drowsiness. If you have any of these symptoms whilst taking Enablex, consult your doctor for advice on changing the dose or considering an alternative treatment. You should not drive or use machines if you are affected by these symptoms.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>3.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>HOW TO TAKE ENABLEX:</strong></p><p>Always take Enablex exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure. If you have the impression that the effect of Enablex is too strong or too weak, talk to your doctor or pharmacist.</p><p><strong>How much Enablex to take:</strong></p><p>The recommended starting dose, including for patients aged over 65 years, is 7.5 mg daily. Depending on your response to Enablex, your doctor may increase your dose to 15 mg daily, two weeks after starting therapy.</p><p>These doses are suitable for people with mild liver problems or people with kidney problems.</p><p>Take Enablex tablets once a day with water, at about the same time each day.</p><p>The tablet may be taken with or without food. Swallow the tablet whole. Do not chew, split or crush it.</p><p><strong>How long to take Enablex:</strong></p><p>Your doctor will tell you how long your treatment with Enablex will last. Do not stop treatment early because you do not see an immediate effect. Your bladder will need some time to adapt. Finish the course of treatment prescribed by your doctor. If you have not noticed any effect by then, discuss it with your doctor.</p><p><strong>If you take more Enablex than you should:</strong></p><p>If you have taken more tablets than you have been told to take, or if someone else accidentally takes your tablets, go to your doctor or hospital for advice immediately. When seeking medical advice, make sure that you take this leaflet and your remaining tablets with you to show them to the doctor.</p><p>People who have taken an overdose may have dry mouth, constipation, headache, indigestion and nasal dryness. Overdose with Enablex may lead to severe symptoms requiring emergency treatment in hospital.</p><p><strong>If you forget to take Enablex:</strong></p><p>If you forget to take Enablex at the usual time, take it as soon as you remember, unless it is the time for your next dose. Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking Enablex:</strong></p><p>It has been shown that taking all doses at the appropriate times can greatly increase the effectiveness of your medicine. Therefore, it is important to keep taking Enablex correctly, as described above. Do not stop taking Enablex until your doctor tells you to. You should not experience any effects when you stop treatment.</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>4.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Possible side effects:</strong></p><p>Like all medicines, Enablex can cause side effects, although not everybody gets them. The side effects caused by Enablex are usually mild and temporary.</p><p>These side effects may occur with certain frequencies, which are defined as follows:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; very common: affects more than 1 patient in 10</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; common: affects 1 to 10 patients in 100</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; uncommon: affects 1 to 10 patients in 1,000</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rare: affects 1 to 10 patients in 10,000</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; very rare: affects less than 1 patient in 10,000</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; not known: frequency cannot be estimated from the available data.</p><p><strong>Some side effects could be serious:</strong></p><p>Serious allergic reactions including swelling, mainly of the face and throat.</p><p><strong>Other side effects:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Very common:</strong></p><p>Dry mouth, constipation.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Common:</strong></p><p>Headache, abdominal pain, indigestion, feeling sick, dry eyes, nasal dryness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Uncommon:</strong></p><p>Fatigue, accidental injury, facial swelling, high blood pressure, diarrhoea, flatulence, inflammation of the mucous membrane of the mouth, increased liver enzymes, swelling, dizziness, sleeplessness, drowsiness, abnormal thinking, runny nose (rhinitis), cough, shortness of breath, dry skin, itching, rash, sweating, visual disturbance including blurred vision, taste disturbance, urinary tract disorder or infection, impotence, discharge and itching in the vagina, bladder pain, inability to empty your bladder.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Not known:</strong></p><p>Depressed mood/mood alterations, hallucination.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>5.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>HOW TO STORE ENABLEX:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the reach and sight of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use after the expiry date which is stated on the carton.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep the blister packs in the outer carton in order to protect from light.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use if the pack is damaged or shows signs of tampering.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store below 25&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>What Enablex contains:</strong></p><p><strong>&nbsp;&nbsp; Enablex 7.5mg:</strong></p><p>- The active substance is darifenacin. Each tablet contains 7.5 mg darifenacin hydrobromide.</p><p>- The other ingredients are calcium hydrogen phosphate anhydrous, hypromellose, magnesium stearate, Opadry&reg; White (00F18296), and purified water.</p><p>&nbsp;&nbsp; <strong>Enablex 15mg:</strong></p><p>- The active substance is darifenacin. Each tablet contains 15 mg darifenacin hydrobromide.</p><p>- The other ingredients are calcium hydrogen phosphate anhydrous, hypromellose, magnesium&nbsp;&nbsp;stearate, Opadry&reg; White (00F18296), Opadry&reg; Yellow (00F12951), Opadry&reg; Red (00F15613),&nbsp;and purified water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                b.What Enablex looks like and contents of the pack:
Enablex 7.5 mg prolonged-release tablets are round shallow convex in shaped tablets (white tablets).
Enablex 15 mg prolonged-release tablets are round shallow convex in shaped tablets (Peach tablets).
The tablets are available in blister packs containing 28 tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>c.Marketing Authorisation Holder:</strong></p><p>Aspen pharma trading limited (APTL)</p><p>3016 Lake Drive</p><p>City West Business Campus</p><p>Dublin</p><p>Ireland</p><p><strong>Manufacturer:</strong></p><p>Aspen Bad Oldesloe GmbH</p><p>Industriestrasse 32-36</p><p>D-23843 Bad Oldesloe</p><p>Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                d. This leaflet was last approved in {December/2018}; version number {003}
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>: ما هو إنابليكس وما هي دواعي استخدامه&nbsp;</strong></p><p><strong>:كيف يعمل إنابليكس</strong></p><p>.يقلل إنابليكس نشاط المثانة مفرطة النشاط، مما يمكن المريض من الانتظار فترة أطول قبل الذهاب إلى المرحاض، ويزيد كمية البول التي يمكن للمثانة حملها</p><p><strong>:دواعي استخدام إنابليكس</strong></p><p>ينتمي إنابليكس إلى فئة من الأدوية ترخي عضلات المثانة. وهو يُستخدم للبالغين لعلاج أعراض حالات فرط نشاط المثانة، مثل الاحتياج المفاجئ للإسراع إلى المرحاض، والاحتياج للذهاب إلى المرحاض بشكل متكرر، و/أو عدم الوصول إلى المرحاض في الوقت المناسب وتبليل المريض نفسه سلس البول الإلحاحي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>:قبل تناول إنابليكس&nbsp;</strong></p><p><strong>:لا تتناول إنابليكس</strong></p><p>إذا كنت مصابا بحساسية (حساسية مفرطة) لمادة داريفيناسين أو أي من مكونات إنابليكس الأخرى-</p><p>(إذا كنت تعاني من احتباس بولي (عدم القدرة على إفراغ المثانة-</p><p>(إذا كنت مصابا باحتباس مَعدي (مشكلات في إفراغ محتويات المعدة-</p><p>إذا كنت تعاني من غلوكوما تضيّق الزاوية غير مسيطر عليه (ارتفاع ضغط العين يصاحبه فقدان البصر في حالة عدم تلقي العلاج المناسب-</p><p>(إذا كنت مصابا بالوهن العضلي الوبيل (مرض يتسم بإجهاد غير طبيعي وضعف عضلات معينة-</p><p>(إذا كنت مصابا بالتهاب القولون التقرحي الحاد أو تضخم القولون السمي (توسع حاد في القولون ناتج عن مضاعفات عدوى أو التهاب-</p><p>إذا كنت مصابا بمشاكل كبدية حادة-</p><p>هناك بعض الأدوية مثل سيكلوسبورين (دواء يستخدم في عمليات الزرع لمنع رفض الأعضاء أو لحالات أخرى، على سبيل المثال، التهاب المفاصل الروماتويدي أو التهاب الجلد التأتبي)، فيراباميل(دواء يُستخدم في خفض ضغط الدم، لضبط نظم القلب أو لعلاج الذبحة الصدرية)،مضادات الفطريات (على سبيل المثال، كيتوكونازول وإيتراكونازول) وبعض مضادات الفيروسات (على سبيل المثال،ريتونافير) التي يجب الامتناع عن تناولها مع إنابليكس</p><p><strong>:توخَ الحرص الشديد عند تناول إنابليكس</strong></p><p>إذا كنت مصابا باعتلال عصبي مستقلي (تلف بالأعصاب التي توصل ما بين المخ والأعضاء الداخلية، والعضلات، والجلد، والأوعية الدموية لتنظيم الوظائف الحيوية، بما في ذلك معدل ضربات القلب، وضغط الدم ووظائف الامعاء)، سيخبرك الطبيب إذا ما كنت مصابا بهذه الحالة</p><p>إذا ما كانت تعاني من حرقة الفؤاد والتَجَشّؤ-</p><p>إذا كنت تواجه صعوبات في التبول وكان تدفق البول لديك ضعيفا-</p><p>إذا كنت مصابا بإمساك حاد (بما يعادل مرتين تبرز أو أقل أسبوعيا-</p><p>&nbsp;إذا كنت مصابا باضطراب الحركية الهضمية-</p><p>إذا كنت مصابا باضطراب انسدادي معوي (أي انسداد في المسالك المعوية أو محتويات المعدة، مثل تضيّق بوابة المعدة، الجزء السفلي من المعدة)،سيخبرك الطبيب إذا ما كنت مصابا بهذه الحالة</p><p>إذا كنت تتناول مستحضرات دوائية بإمكانها التسبب في الإصابة بالتهاب المريء أو تفاقم حالته مثل الفسفونات الثنائية التي تؤخذ عن طريق الفم فئة من المستحضرات الدوائية التي تمنع فقدان كتلة العظم وتُستخدم في علاج هشاشة العظام</p><p>إذا كنت تتلقى علاجا لغلوكوما تضيّق الزاوية-</p><p>&nbsp;إذا كنت مصابا بمشاكل كبدية-</p><p>إذا كنت مصابا بمشاكل كلوية-</p><p>إذا كنت مصاب ا بأمراض قلبية-</p><p>إذا كان أي مما سبق ينطبق عليك، اخبر طبيبك قبل تناول إنابليكس</p><p>(خلال فترة العلاج بإنابليكس، أخبر طبيبك على الفور وتوقف عن تناول هذا لدواء في حالة حدوث توّرم في الوجه، أو الشفتين، أو اللسان و/أو الحلق (علامات الوذمة الوعائية</p><p><strong>:(الاستخدام للأطفال (أقل من 18 عاما</strong></p><p>لا يُوصى باستخدام إنابليكس للأطفال</p><p><strong>:تناول الأدوية الأخرى مع إنابليكس</strong></p><p>يُرجى إخبار طبيبك أو الصيدلي إن كنت تتناول أو تناولت مؤخراً أي أدوية أخرى، بما في ذلك الأدوية التي تُصرف بدون وصفة طبية فهذا هام بوجه خاص إذا كنت تتناول أي مما يلي، حيث قد يحتاج طبيبك إلى تعديل جرعتك من إنابليكس و/أو المنتج الآخر</p><p>(مضادات حيوية محددة (على سبيل المثال إريثروميسين، وكلاريثرومايسين، وريفامبيسين-</p><p>(مضادات الفطريات (على سبيل المثال، كيتوكونازول وإيتراكونازول-</p><p>(مضادات الفيروسات (على سبيل المثال، نلفينافير وريتونافير-</p><p>(مضادات الذهان (على سبيل المثال، ثَيُوريدازين-</p><p>(مضادات اكتئاب محددة (على سبيل المثال إيمبيرامين-</p><p>(مضادات اختلاج محددة (مثل كربامازيبين وباربتيورات-</p><p>( أدوية محددة تستخدم في علاج المشاكل القلبية (على سبيل المثال، فليكاينيد، وفيراباميل، وديجوكسين-</p><p>(مضادات المسكارين الأخرى (على سبيل المثال تولتيرودين، وأوكسي بوتينين وفلافوكسات-</p><p>يُرجى إخبار طبيبك إذا كنت تتناول أي منتجات تحتوي نبتة القديس يوحنا المثقبة</p><p><strong>:تناول إنابليكس مع الطعام والشراب</strong></p><p>.لا يؤثر تناول الطعام على إنابليكس. قد يتفاعل عصير الغريب فروت مع إنابليكس. إلا أن تعديل جرعات إنابليكس ليس ضروريا</p><p><strong>الحمل والرضاعة الطبيعية</strong></p><p><strong>إذا كنتِ حاملاً أو تعتقدين أنكِ قد تكونين حاملاً، أخبري طبيبك</strong></p><p>لا يوصى بتناول إنابليكس خلال فترة الحمل</p><p><strong>إذا كنتِ ترضعين رضاعة طبيعية، اطلبي من طبيبك المشورة</strong>.</p><p>إذا كنتِ ترضعين رضاعة طبيعية، اطلبي من طبيبك المشورة. يجب توخي الحذر عند تناول إنابليكس خلال فترة الرضاعة الطبيعية</p><p><strong>القيادة واستخدام الآلات</strong></p><p>قد يتسبب إنابليكس في آثار مثل الدوخة، أو تشوش الرؤية، أو صعوبة في النوم أو النعاس. إذا عانيت من أي من هذه الأعراض خلال العلاج بإنابليكس، اطلب من طبيبك المشورة لتغيير الجرعة أو التفكير في علاج بديل. يجب عليك الامتناع عن القيادة أو استخدام الآلات إذا أصبت بهذه الأعراض</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>&nbsp;:</strong><strong>كيفية تناول إنابليكس</strong></p><p>تناول إنابليكس دائمًا على النحو الذي يصفه طبيبك بالضبط. يجب أن تستشير طبيبك أو الصيدلي إن لم تكن متأكداً. إذا كان لديك الانطباع أن تأثير إنابليكس أقوى مما ينبغي أو أضعف مما ينبغي، تحدث إلى طبيبك أو الصيدلي</p><p><strong>:الجرعة الواجب تناولها من إنابليكس</strong></p><p>الجرعة الأولية الموصى بها، بما في ذلك للمرضى الذين تجاوزوا 65 عاما،ً هي 7.5 ملغ يوميا.ً بحسب استجابتك لإنابليكس، قد يرفع طبيبك الجرعة إلى 15 ملغ يوميا بعد مرور أسبوعين من بدء العلاج</p><p>.هذه الجرعات مناسبة للمصابين بمشاكل كبدية طفيفة أو المصابين بمشاكل كلوية</p><p>.تُؤخذ أقراص إنابليكس مرة يوميا مع الماء، تقريبا في نفس الوقت تقريبا كل يوم</p><p>.يمكن تناول الأقراص مع الطعام أو بدونه. ابتلع القرص كاملاً. لا تمضغ الأقراص، أو تقسمها أو تسحقها</p><p><strong>:كم تمتد فترة العلاج بأقراص إنابليكس</strong></p><p>سيخبرك الطبيب بمدة العلاج بأقراص إنابليكس لا تنقطع عن تناول العلاج قبل الوقت المحدد إن لم ترى نتيجة فورية ستحتاج مثانتك إلى بعض الوقت لتتكيف أتم الفترة العلاجية التي وصفها لك طبيبك إن لم ترى أي أثر بهذا الوقت، يمكنك مناقشة ذلك مع طبيبك</p><p><strong>:في حالة تناولك أكثر مما يفترض من إنابليكس</strong></p><p>إذا تناولت الأقراص بكمية أكثر من التي وصفت لك، أو تناول أحدهم أقراصك عن طريق الخطأ، اذهب إلى طبيبك أو المستشفى للاستشارة على الفور. عند طلب المشورة الطبية،احرص على أخذ هذه النشرة وأي أقراص متبقية لديك لتريها للطبيب</p><p>.قد يعاني الأفراد الذين تناولوا جرعة مفرطة من جفاف الفم، والإمساك، والصداع، وعسر هضم، وجفاف الأنف</p><p>&nbsp;.قد تؤدي الجرعة المفرطة من إنابليكس إلى أعراض حادة تتطلب العلاج الطارئ في المستشفى</p><p><strong>:إذا نسيت تناول إنابليكس</strong></p><p>.إذا نسيت تناول إنابليكس في الوقت المعتاد، تناوله بمجرد أن تتذكر، ما لم يكن موعد الجرعة التالية قد حل بالفعل.لا تتناول جرعة مضاعفة لتعويض الجرعة التي نسيتها</p><p><strong>:في حال الانقطاع عن تناول إنابليكس</strong></p><p>لقد تبين أن تناول جميع الجرعات في الأوقات المناسبة يمكن أن يزيد فعالية الدواء بشكل كبير. لذا، من الهام المداومة على تناول إنابليكس بالشكل الصحيح على النحو الموضح أعلاه. لا تنقطع عن تناول إنابليكس إلى أن يخبرك الطبيب بذلك. لا يفترض أن تظهر عليك أي آثار عند الانقطاع عن العلاج</p><p>.إن كان لديك أي استفسارات أخرى حول استخدام هذا المنتج، اسأل طبيبك أو الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p><strong>:&nbsp;</strong><strong>الآثار الجانبية المحتملة</strong></p><p>مثل جميع الأدوية، يمكن أن يسبب إنابليكس آثاراً جانبية، على الرغم من أنه ليس بالضرورة أن يعاني منها الجميع. عادة ما تكون الآثار</p><p>.الجانبية الناتجة عن استخدام إنابليكس طفيفة ومؤقتة</p><p>:قد تظهر هذه الآثار الجانبية بمعدلات تكرار محددة، موضحة فيما يلي</p><p>&nbsp; &nbsp; .شائعة جدا:ً تؤثر على أكثر من 1 من كل 10 مرضى-</p><p>.شائعة: تؤثر على 1 إلى 10 من كل 100 مريض-</p><p>.غير شائعة: تؤثر على 1 إلى 10 من كل 1000 مريض-</p><p>.نادرة: تؤثر على 1 إلى 10 من كل 10000 مريض-</p><p>.نادرة جدا:ً تؤثر على أقل من 1 من كل 10000 مريض-</p><p>.غير معروف: لا يمكن تقدير مدى التكرار من البيانات المتوفرة-</p><p><strong>:يمكن أن تكون بعض الآثار الجانبية خطيرة</strong></p><p>.ردود الفعل التحسسية الخطيرة تتضمن التوّرم، بشكل رئيسي في الوجه والحلق<strong>&nbsp;</strong></p><p><strong>الآثار الجانبية الأخرى&nbsp;</strong></p><p><strong>:شائعة جد اً-</strong></p><p>جفاف الفم، إمساك<strong>&nbsp;</strong></p><p><strong>&nbsp; :</strong><strong>شائعة</strong><strong>-</strong></p><p>.صداع، ألم في البطن، عسر هضم، غثيان، جفاف العينين، جفاف بالأنف</p><p><strong>:غير شائعة-</strong></p><p>إجهاد، الإصابة العرضية، تورم الوجه، ارتفاع ضغط الدم، إسهال، تطبل البطن، التهاب الأغشية المخاطية بالفم، ارتفاع الإنزيمات الكبدية، التوّرم، الدوّار، الأرق، النعاس، أفكار غير طبيعية، رشح (التهاب الأنف)، سعال، ضيق التنفس، جفاف البشرة، حكة، طفح جلدي، تعرّق، اضطراب بصري يتضمن تشوش الرؤية، اضطراب في التذوق، خلل أو عدوى في المسالك البولية، الضعف الجنسي، إفرازات وحكة في المهبل، ألم في المثانة، عدم القدرة على إفراغ المثانة<br />&nbsp;</p><p><strong>&nbsp;</strong><strong>غير معروفة-</strong></p><p>مزاج اكتئابي/تغيرات مزاجية، هلوسة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>:كيفية تخزين إنابليكس</strong></p><p>.يُحفظ بعيداً عن متناول ومرأى الأطفال-</p><p>.لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية الموضح على العلبة الكرتونية-</p><p>.تُحفظ الشرائط في العلبة الكرتونية الخارجية لحمايتها من الضوء-</p><p>.لا تستخدم الدواء إذا كانت العبوة الكرتونية تالفة أو تظهر عليها آثار عبث-</p><p>.يخزن في درجة حرارة أقل من 25 درجة مئوية-</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>:أ. محتويات إنابليكس</strong></p><p><strong>:إنابليكس 7.5 ملغ</strong></p><p>.المادة الفعالة هي داريفيناسين يحتوي كل قرص على&nbsp; 7.5 ملغ داريفيناسين هيدروبروميد-</p><p>.المكونات الأخرى هي فوسفات الكالسيوم أحادي الهيدروجين اللامائي، هيبروميلوز، ستيارات المغنيسيوم، أوبادري &reg; أبيض (00 إف 18296 )، وماء منقى-</p><p><strong>:إنابليكس 15 ملغ</strong></p><p>.المادة الفعالة هي داريفيناسين. يحتوي كل قرص على 15 ملغ داريفيناسين هيدروبروميد-</p><p>-المكونات الأخرى هي فوسفات الكالسيوم أحادي الهيدروجين اللامائي، هيبروميلوز، ستيارات&nbsp; أبيض ( &reg; المغنيسيوم، أوبادري 00 إف 18296 أصفر ) &reg; (، أوبادري 00 إف 12951 أحمر ) &reg; (، أوبادري 00 إف 15613 )، وماء منقى</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            ب. كيف يبدو إنابليكس وما هي محتويات العبوة:
إنابليكس 7.5 ملغ أقراص ممتدة المفعول، أقراص دائرية الشكل محدبة ومسطحة (أقراص بيضاء).
إنابليكس 15 ملغ أقراص ممتدة المفعول، أقراص دائرية الشكل محدبة ومسطحة (أقراص ذات لون خوخي).
الأقراص متوفرة في شرائط في عبوات كرتونية تحتوي على 28 قرصا.

        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>&nbsp;:مالك حق التسويق</strong></p><p>(APTL)أسبن فارما تريدينغ المحدودة</p><p>3016 ليك درايف،</p><p>مجمع الأعمال سيتي ويست</p><p>دبلن</p><p>أيرلندا</p><p><strong>:الشركة المصنعة</strong></p><p>شركة أسبن باد أولدسلو المحدودة</p><p>المنطقة الصناعية 32 - 36 ،</p><p>دي - 23843 باد أولدسلو</p><p>ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ث. تمت آخر مراجعة لهذه النشرة في ديسمبر 2018 ، رقم النسخة {003}
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Enablex15 mg prolonged-release tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 15 mg of darifenacin (as hydrobromide) 
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Prolonged-release tablet
Enablex 15 mg prolonged-release tablets are round shallow convex in shaped tablets (Peach tablets).

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with overactive bladder syndrome.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Adults</u></p><p>The recommended startingdose is 7.5 mg daily. After 2 weeks of starting therapy, patients should be reassessed. For those patients requiring greater symptom relief, the dose may be increased to 15 mg daily, based on individual response.</p><p><u>Elderly patients (&ge; 65 years)</u></p><p>The recommended startingdose for the elderly is 7.5 mg daily. After 2 weeks of starting therapy, patients should be reassessed for efficacy and safety. For those patients who have an acceptable tolerability profile but require greater symptom relief, the dose may be increased to 15 mg daily, based on individual response (see section 5.2).</p><p><u>Paediatric population</u></p><p>Enablex is not recommended for use in children below 18 years of age due to a lack of data on safety and efficacy.</p><p><u>Renal impairment</u></p><p>No dose adjustment is required in patients with impaired renal function. However, caution should be exercised when</p><p>treating this population (see section 5.2).</p><p><u>Hepatic impairment</u></p><p>No dose adjustment is required in patients with mild hepatic impairment (Child Pugh A). However, there is a risk of increased exposure in this population</p><p>(see section 5.2).</p><p>Patients with moderate hepatic impairment (Child Pugh B) should only be treated if the benefit outweighs the risk, and the dose should be restricted to 7.5 mg daily (see section 5.2). Enablex is contraindicated in patients with severe hepatic impairment (Child Pugh C) (see section 4.3).</p><p><u>Patients receiving concomitant treatment with substances that are potent inhibitors of CYP2D6 or moderate inhibitors of</u> <u>CYP3A4</u></p><p>In patients receiving substances that are potent CYP2D6 inhibitors, such as paroxetine, terbinafine, quinidine and cimetidine, treatment should start with the 7.5 mg dose. The dose may be titrated to 15 mg daily to obtain an improved clinical response provided the dose is well tolerated. However, caution should be exercised.</p><p>In patients receiving substances that are moderate CYP3A4 inhibitors, such as fluconazole, grapefruit juice and erythromycin, the recommended startingdose is 7.5 mg daily. The dose may be titrated to 15 mg daily to obt ain an improved clinical response provided the dose is well tolerated. However, caution should be exercised.</p><p><u>Method of administration</u></p><p>Enablex is for oral use. The tablets should be taken once daily with liquid. They can be taken with or without food, and must be swallowed whole and not chewed, divided or crushed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Enablex is contraindicated in patients with:
-	Hypersensitivity to the active substance or to any of the excipients.
-	Urinary retention.
-	Gastric retention.
-	Uncontrolled narrow-angle glaucoma.
-	Myasthenia gravis.
-	Severe hepatic impairment (Child Pugh C).
-	Severe ulcerative colitis.
-	Toxic megacolon.
-	Concomitant treatment with potent CYP3A4 inhibitors (see section 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Enablex should be administered with caution to patients with autonomic neuropathy, hiatus hernia, clinically significant bladder outflow obstruction, risk for urinary retention, severe constipation or gastrointestinal obstructive disorders, such as pyloric stenosis.</p><p>Enablex should be used with caution in patients being treated for narrow-angle glaucoma (see section 4.3).</p><p>Other causes of frequent urination (heart failure or renal disease) should be assessed before treatment with Enablex. If urinary tract infection is present, an appropriate antibacterial therapy should be started.</p><p>Enablex should be used with caution in patients with risk of decreased gastrointestinal motility, gastro-oesophageal reflux and/or who are concurrently taking medicinal products (such as oral bisphosphonates) that can cause or exacerbate oesophagitis.</p><p>Safety and efficacy have not yet been established in patients with a neurogenic cause for detrusor over activity.</p><p>Caution should be used when prescribing antimuscarinics to patients with pre-existing cardiac diseases.</p><p>As with other antimuscarinics, patients should be instructed to discontinue Enablex and seek immediate medical attention if they experience oedema of the tongue or laropharynx, or difficulty breathing (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Effects of other medicinal products on darifenacin</u></p><p>Darifenacin metabolism is primarily mediated by the cytochrome P450 enzymes CYP2D6 and CYP3A4. Therefore, inhibitors of these enzymes may increase darifenacin exposure.</p><p><em>CYP2D6 inhibitors</em></p><p>In patients receiving substances that are potent CYP2D6 inhibitors (e.g. paroxetine, terbinafine, cimetidine and quinidine) the recommended startingdose should be 7.5 mg daily. The dose may be titrated to 15 mg daily to obtain an improved clinical response provided the dose is well tolerated. Concomitant treatment with potent CYP2D6 inhibitors results in an increase in exposure (e.g. of 33% with 20 mg paroxetine at the 30 mg dose of darifenacin).</p><p><em>CYP3A4 inhibitors</em></p><p>Darifenacin should not be used together with potent CYP3A4 inhibitors (see section 4.3) such as protease inhibitors (e.g. ritonavir), ketoconazole and itraconazole. Potent P-glycoprotein inhibitors such as ciclosporin and verapamil should also be avoided. Co-administration of darifenacin 7.5 mg with the potent CYP3A4 inhibitor ketoconazole 400 mg resulted in a 5-fold increase in steady-state darifenacin AUC. In subjects who are poor metabolisers, darifenacin exposure increased approximately 10-fold. Due to a greater contribution of CYP3A4 after higher darifenacin doses, the magnitude of the effect is expected to be even more pronounced when combining ketoconazole with darifenacin 15 mg.</p><p>When co-administered with moderate CYP3A4 inhibitors such as erythromycin, clarithromycin, telithromycin, fluconazole and grapefruit juice, the recommended starting dose of darifenacin should be 7.5 mg daily. The dose may be titrated&nbsp;to&nbsp;15&nbsp;mg daily to obtain an improved clinical &nbsp;response provided the dose is well tolerated. Darifenacin AUC24 and Cmax from&nbsp;30&nbsp;mg&nbsp;once-daily&nbsp;dosing&nbsp;in&nbsp;subjects&nbsp;who&nbsp;are&nbsp;extensive&nbsp;metabolisers&nbsp;were&nbsp;95%&nbsp;and 128% higher when erythromycin (moderate CYP3A4 inhibitor) was co-administered with darifenacin than when darifenacin was taken alone.</p><p><em>Enzyme inducers</em></p><p>Substances that are inducers of CYP3A4, such as rifampicin, carbamazepine, barbiturates and St John&acute;s wort (<em>Hypericum perforatum</em>) are likely to decrease the plasma concentrations of darifenacin.</p><p><u>Effects of darifenacin on other medicinal products</u></p><p><em>CYP2D6 substrates</em></p><p>Darifenacin is a moderate inhibitor of the enzyme CYP2D6. Caution should be exercised when darifenacin is used concomitantly with medicinal products that are predominantly metabolised by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine, or tricyclic antidepressants such as imipramine. The effects of darifenacin on the metabolism of CYP2D6 substrates are mainly clinically relevant for CYP2D6 substrates which are individually dose titrated.</p><p><em>CYP3A4 substrates</em></p><p>Darifenacin treatment resulted in a modest increase in the exposure of the CYP3A4 substrate midazolam. However the data available do not indicate that darifenacin changes either midazolam clearance or bioavailability. It can therefore be concluded that darifenacin administration does not alter the pharmacokinetics of CYP3A4 substrates <em>in vivo</em>. The interaction with midazolam lacks clinical relevance, and therefore no dose adjustment is needed for CYP3A4 substrates.</p><p><em>Warfarin</em></p><p>Standard therapeutic prothrombin time monitoring for warfarin should be continued. The effect of warfarin on prothrombin time was not altered when co-administered with darifenacin.</p><p><em>Digoxin</em></p><p>Therapeutic drug monitoring for digoxin should be performed when initiating and ending darifenacin treatment as well as changing the darifenacin dose. Darifenacin 30 mg once daily (two times greater than the recommended daily dose) co- administered&nbsp;with digoxin&nbsp; at steady state resulted in a small increase in digoxin&nbsp; exposure (AUC: 16% and Cmax:&nbsp;20%). The increase in digoxin exposure could be caused by competition between darifenacin and digoxin for P-glycoprotein. Other transporter-related interactions cannot be excluded.</p><p><em>Antimuscarinic agents</em></p><p>As with any other antimuscarinic agents, concomitant use of medicinal products that possess antimuscarinic properties, such as oxybutynin, tolterodine and flavoxate, may result in more pronounced therapeutic and side effects. The potentiation of anticholinergic effects with anti-parkinson agents and tricyclic antidepressants may also occur if antimuscarinic agents are used concurrently with such medicinal products. However, no studies involving the interaction with anti-parkinson agents and tricyclic antidepressants have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Fertility</u></p><p>There are no human fertility data for darifenacin. Darifenacin had no effect on male or female&nbsp; fertility in rats or any effect in the reproductive organs of either sex in rats and dogs (for details, see section 5.3). Women of child bearing potential should be made aware of the lack of fertility data, and Enablex should only be given after consideration of individual risks and benefits.</p><p><u>Pregnancy</u></p><p>There are limited amount of data from the use of darifenacin in pregnant women. Studies in animals have shown toxicity to parturition (for details, see section 5.3). Enablex is not recommended during pregnancy.</p><p><u>Breast-feeding</u></p><p>Darifenacin is excreted in the milk of rats. It is not known whether darifenacin is excreted in human milk. A risk to the nursing child cannot be excluded. A decision whether to avoid breast-feeding or to abstain from Enablex therapy during lactation should be based on a benefit and risk comparison.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies of the effects of Enablex on the ability to drive and use machines have been performed. As with other antimuscarinic agents, Enablex may produce effects such as dizziness, blurred vision, insomnia and somnolence. Patients experiencing these side effects should not drive or use machines. For Enablex, these side effects have been reported to be uncommon.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Consistent with the pharmacological profile, the most commonly reported adverse reactions were dry mouth (20.2% and 35% for the 7.5 mg and 15 mg dose, respectively, 18.7% after flexible dose titration, and 8% - 9% for placebo) and constipation (14.8% and 21% for the 7.5 mg and 15 mg dose, respectively, 20.9% after flexible dose titration, and 5.4% - 7.9% for placebo). Anticholinergic effects, in general, are dose-dependent.</p><p>However, the patient discontinuation rates due to these adverse reactions were low (dry mouth: 0% - 0.9% and constipation: 0.6% - 2.2% for darifenacin, depending on the dose; and 0% and 0.3% for placebo, for dry mouth and constipation, respectively).</p><p>Table 1: Adverse reactions with Enablex7.5 mg and 15 mg prolonged-release tablets</p><p>Frequency estimate: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), not known (cannot be estimated from the available data)</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Urinary tract infection</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Insomnia, thinking abnormal</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous systemdisorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Dizziness, dysgeusia, somnolence</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dry eye</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Visual disturbance, including vision blurred</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hypertension</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Nasal dryness</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Dyspnoea, cough, rhinitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Constipation, dry mouth</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Abdominal pain, nausea, dyspepsia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Flatulence, diarrhoea, mouth ulceration</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rash, dry skin, pruritus, hyperhidrosis</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Angioedema</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Urinary retention, urinary tract disorder, bladder pain</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Reproductive systemand breast disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Erectile dysfunction, vaginitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Oedema peripheral, asthenia, face oedema, oedema</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Aspartate aminotransferase increased, alanine aminotransferase increased</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Injury, poisoning, and procedural complications</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Injury</p></td></tr></tbody></table><p>In the pivotal clinical trials with doses of Enablex7.5 mg and 15 mg, adverse reactions were reported as presented in the table above. Most of the adverse reactions were of mild or moderate intensity and did not result in discontinuation in the majority of the patients.</p><p>Treatment with Enablex may possibly mask symptoms associated with gallbladder disease. However, there was no association between the occurrence of adverse events related to the biliary system in darifenacin-treated patients and increasing age.</p><p>The incidence of adverse reactions with the doses of Enablex7.5 mg and 15 mg decreased during the treatment period up to 6 months. A similar trend is also seen for the discontinuation rates.</p><p><u>Post-marketing experience</u></p><p>The following events have been reported in association with darifenacin use in worldwide post-marketingexperience: generalised hypersensitivity reactions including angioedema, depressed mood/mood alterations, hallucination. Because these spontaneously reported events are from the worldwide post-marketingexperience, the frequency of events cannot be estimated from the available data.</p><p>To report any side effect(s):</p><p>- Saudi Arabia:</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>-The National Pharmacovigilance and Drug Safety Centre (NPC):<br />-Fax: 00966112057662<br />-SFDA call center 19999<br />-Toll free phone: 8002490000<br />-E-mail: npc.drug@sfda.gov.sa<br />-Website: www.sfda.gov.sa/npc</td></tr></tbody></table><p>- Other GCC States:</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>-Please contact the relevant competent authority.</td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Enablex has been administered in clinical trials at doses up to 75 mg (five times maximum therapeutic dose). The most common adverse reactions seen were dry mouth, constipation, headache, dyspepsia and nasal dryness. However, overdose with darifenacin can potentially lead to severe anticholinergic&nbsp; effects and should be&nbsp; treated accordingly.&nbsp; Therapy should be aimed at reversing the anticholinergic symptoms under careful medical supervision. The use of agents such as physostigmine can assist in reversing such symptoms.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Urinary antispasmodic, ATC code: G04BD10.</p><p>Darifenacin&nbsp;is&nbsp;a selective muscarinic M 3 receptor antagonist (M 3 SRA) <em>in vitro</em>. The M 3 receptor is the major subtype that controls urinary bladder muscle contraction. It is not known whether this selectivity for the M 3 receptor translates into any clinical advantage when treating symptoms of overactive bladder syndrome.</p><p>Cystometric studies performed with darifenacin in patients with involuntary bladder contractions showed increased bladder capacity, increased volume threshold for unstable contractions and diminished frequency of unstable detrusor contractions.</p><p>Treatment with Enablex administered at dosages of 7.5 mg and 15 mg daily has been investigated in four double-blind, Phase III, randomised, controlled clinical studies in male and female patients with symptoms of overactive bladder.&nbsp; As seen in Table 2 below, a pooled analysis of 3 of the studies for the treatment with both Enablex7.5 mg and 15 mg provided a statistically significant improvement in the primary endpoint, reduction in incontinence episodes, versus placebo.</p><p>Table 2: Pooled analysis of data from three Phase III clinical studies assessing fixed doses of 7.5 mg and 15 mg Enablex</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Dose</p></td><td rowspan="2" style="vertical-align:top"><p>N</p></td><td colspan="4" style="vertical-align:top"><p>Incontinence episodes per week</p></td><td rowspan="2" style="vertical-align:top"><p>95% CI</p></td><td rowspan="2" style="vertical-align:top"><p>P value2</p></td></tr><tr><td style="vertical-align:top"><p>Baseline (median)</p></td><td style="vertical-align:top"><p>Week 12 (median)</p></td><td style="vertical-align:top"><p>Change from baseline (median)</p></td><td style="vertical-align:top"><p>Differences from placebo1 (median)</p></td></tr><tr><td style="vertical-align:top"><p>Enablex7.5 mg</p><p>once daily</p></td><td style="vertical-align:top"><p>335</p></td><td style="vertical-align:top"><p>16.0</p></td><td style="vertical-align:top"><p>4.9</p></td><td style="vertical-align:top"><p>-8.8 (-68%)</p></td><td style="vertical-align:top"><p>-2.0</p></td><td style="vertical-align:top"><p>(-3.6, -0.7)</p></td><td style="vertical-align:top"><p>0.004</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>271</p></td><td style="vertical-align:top"><p>16.6</p></td><td style="vertical-align:top"><p>7.9</p></td><td style="vertical-align:top"><p>-7.0 (-54%)</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Enablex15 mg</p><p>once daily</p></td><td style="vertical-align:top"><p>330</p></td><td style="vertical-align:top"><p>16.9</p></td><td style="vertical-align:top"><p>4.1</p></td><td style="vertical-align:top"><p>-10.6 (-</p><p>77%)</p></td><td style="vertical-align:top"><p>-3.2</p></td><td style="vertical-align:top"><p>(-4.5, -2.0)</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>384</p></td><td style="vertical-align:top"><p>16.6</p></td><td style="vertical-align:top"><p>6.4</p></td><td style="vertical-align:top"><p>-7.5 (-58%)</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr></tbody></table><p>1 Hodges Lehmann estimate: median difference from placebo in change from baseline</p><p>2 Stratified Wilcoxon test for difference from placebo.</p><p>Enablex7.5 mg and 15 mg doses significantly reduced both the severity and number of urinary urgency episodes and the number of micturitions, while significantly increasing the mean volume voided from baseline.</p><p>Enablex7.5 mg and 15 mg were associated with statistically significant improvements over placebo in some aspects of quality of life as measured by the Kings Health Questionnaire including incontinence impact, role limitations, social limitations and severity measures.</p><p>For both doses of 7.5 mg and 15 mg, the percentage median reduction from baseline in the number of incontinence episodes per week was similar between males and females. The observed differences from placebo for males in terms of percentage and absolute reductions in incontinence episodes was lower than for females.</p><p>The effect of treatment with 15 mg and 75 mg of darifenacin on QT/QTc interval was evaluated in a study in 179 healthy adults (44% male: 56% females) aged 18 to 65 for 6 days (to steady state). Therapeutic and supra-therapeutic doses of darifenacin resulted in no increase in QT/QTc interval prolongation from baseline compared to placebo at maximum darifenacin exposure.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Darifenacin is metabolised by CYP3A4 and CYP2D6. Due to genetic differences, about 7% of the Caucasians lack the CYP2D6 enzyme and are said to be poor metabolisers. A few percent of the population have increased CYP2D6 enzyme levels (ultrafast metabolisers). The information below applies to subjects who have normal CYP2D6 activity (extensive metabolisers) unless otherwise stated.</p><p><u>Absorption</u></p><p>Due to extensive first-pass metabolism darifenacin has a bioavailability of approximately 15% and 19% after 7.5 mg and 15 mg daily doses at steady state. M aximum plasma levels are reached approximately 7 hours after administration of the prolonged-release tablets and steady-state plasma levels are achieved by the sixth day of administration. At steady state, peak-to-trough fluctuations in darifenacin concentrations are small (PTF: 0.87 for 7.5 mg and 0.76 for 15 mg), thereby</p><p>maintaining therapeutic plasma levels over the dosing interval. Food had no effect on darifenacin pharmacokinetics during multiple-dose administration of prolonged-release tablets.</p><p><u>Distribution</u></p><p>Darifenacin is a lipophilic base and is 98% bound to plasma proteins (primarily to alpha-1-acid-glycoprotein). The steady- state&nbsp;volume of distribution (Vss)&nbsp;is estimated to be 163 litres.</p><p><u>Metabolism</u></p><p>Darifenacin is extensively metabolised by the liver following oral administration.</p><p>Darifenacin undergoes significant metabolism by cytochrome CYP3A4 and CYP2D6 in the liver and by CYP3A4 in the gut wall. The three main metabolic routes are as follows:</p><p>monohydroxylation in the dihydrobenzofuran ring; dihydrobenzofuran ring opening and</p><p>N-dealkylation of the pyrrolidine nitrogen.</p><p>The initial products of the hydroxylation and N-dealkylation pathways are major circulating metabolites but none contribute significantly to the overall clinical effect of darifenacin.</p><p>The pharmacokinetics of darifenacin at steady state are dose-dependent, due to saturation of the CYP2D6 enzyme. Doubling the darifenacin dose from 7.5 mg to 15 mg result in a 150% increase in steady -state exposure. This dose-</p><p>dependency is probably caused by saturation of the CYP2D6 catalysed metabolism possibly together with some saturation</p><p>of CYP3A4-mediated gut wall metabolism.</p><p><u>Excretion</u></p><p>Following administration of an oral dose of 14C-darifenacin solution to healthy volunteers, approximately 60% of the</p><p>radioactivity was recovered in the urine and 40% in the faeces. Only a small percentage of the excreted dose was unchanged darifenacin (3%). Estimated darifenacin clearance is 40 litres/hour. The elimination half-life of darifenacin following chronic dosing is approximately 13-19 hours.</p><p><u>Special patient population</u></p><p><em>Gender</em></p><p>A population pharmacokinetic analysis of patient data indicated that darifenacin exposure was 23% lower in males than females (see section 5.1).</p><p><em>Elderly patients</em></p><p>A population pharmacokinetic analysis of patient data indicated a trend for clearance to decrease with age (19% per decade based on Phase III population pharmacokinetic analysis of patients aged 60&ndash;89 years), see section 4.2.</p><p><em>Paediatric patients</em></p><p>The pharmacokinetics of darifenacin have not been established in the paediatric population.</p><p><em>CYP2D6 poor metabolisers</em></p><p>The metabolism of darifenacin in CYP2D6 poor metabolisers is principally mediated by CYP3A4. In one pharmacokinetic study the steady-state exposure in poor metabolisers was 164% and 99% higher during treatment with 7.5 mg and 15 mg once daily, respectively. However, a population pharmacokinetic analyses of Phase III data indicated that on average steady-state exposure is 66% higher in poor metabolisers than in extensive metabolisers. There was considerable overlap between the ranges of exposures seen in these two populations (see section 4.2).</p><p><em>Renal insufficiency</em></p><p>A small study of subjects (n=24) with varying degrees of renal impairment (creatinine clearance between 10 ml/min and 136 ml/min) given darifenacin 15 mg once daily to steady state demonstrated no relationship between renal function and darifenacin clearance (see section 4.2).</p><p><em>Hepatic insufficiency</em></p><p>Darifenacin&nbsp; pharmacokinetics were investigated in subjects with mild (Child Pugh A) or moderate (Child Pugh B)</p><p>impairment of hepatic function given darifenacin 15 mg once daily to steady state. Mild hepatic impairment had no effect on the pharmacokinetics of darifenacin. However, protein binding of darifenacin was affected by moderate hepatic</p><p>impairment. Unbound darifenacin exposure was estimated to be 4.7-fold higher in subjects with moderate hepatic</p><p>impairment than subjects with normal hepatic function (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential. There were no effects on fertility in male and female rats treated at oral doses&nbsp;up to 50 mg/kg/day&nbsp; (78 times the AUC0-24h of&nbsp;free plasma concentration at maximum&nbsp; recommended&nbsp; human dose [MRHD]). There were no effects on reproductive organs in either sex in dogs treated for 1 year at oral doses up to 6 mg/kg/day&nbsp; (82 times the AUC0-24h of&nbsp;free&nbsp;plasma&nbsp;concentration&nbsp;at&nbsp;MRHD).&nbsp;Darifenacin&nbsp;was&nbsp;not&nbsp;teratogenic&nbsp;in&nbsp;rats and rabbits at doses up to 50 and 30 mg/kg/day, &nbsp;respectively. At the dose of 50 mg/kg/day&nbsp; in rats (59 times the AUC0-24h of&nbsp;free plasma concentration at MRHD), delay in the ossification of the sacral and caudal vertebrae was observed. At the dose of 30&nbsp;mg/kg/day&nbsp; in rabbits (28 times the AUC0-24hof&nbsp;free&nbsp;plasma&nbsp;concentration&nbsp;at MRHD), maternal toxicity and foetotoxicity (increased post implantation loss and decreased number of viable foetuses per lit ter) were observed. In peri and post-natal studies in rats, dystocia, increased foetal deaths <em>in utero</em>and toxicity to post-natal development (pup body weight and development&nbsp;land&nbsp;marks)&nbsp;were observed at systemic exposure levels up to 11 times the AUC0-24h of&nbsp;free&nbsp;plasma concentration at MRHD.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Calcium hydrogen phosphate anhydrous</p><p>Hypromellose</p><p>Magnesium stearate</p><p>Opadry&reg; White (00F18296)</p><p>Opadry&reg; Yellow (00F12951)</p><p>Opadry&reg; Red (00F15613)</p><p>Purified water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep the blister packs in the outer carton in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clear PVC/CTFE/aluminium or PVC/PVDC/aluminium blisters in cartons containing 7, 14, 28, 49, 56 or 98 tablets as unit pack or in multipacks containing 140 (10x14) tablets.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aspen pharma trading limited (APTL)
3016 Lake Drive, City West Business Campus Dublin
Ireland

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                6/01/2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>